Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PLRX source : Www.biospace.com save search
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
MRKR | $4.25 3.65% 3.52% 15K
|
Consumer Services
|
| O: -1.2%
H: 4.88%
C: 3.17%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events - February 7, 2024
Published: 2024-02-07 (Crawled : 15:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 0.0%
H: 0.93%
C: -0.87%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events - May 10, 2023
Published: 2023-05-10 (Crawled : 15:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 1.55%
H: 3.59%
C: 0.74%
therapeutics
Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
Published: 2023-03-08 (Crawled : 01:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.45%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.4%
H: 0.32%
C: -0.42%
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -0.36%
H: 2.8%
C: 2.15%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events - March 1, 2023
Published: 2023-03-01 (Crawled : 18:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -0.56%
H: 1.8%
C: -0.79%
therapeutics
Pliant Therapeutics to Participate in Upcoming Investor Events
Published: 2023-02-07 (Crawled : 14:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: -1.34%
therapeutics
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-12-15 (Crawled : 21:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -1.72%
H: 3.29%
C: 3.02%
pln-7480 treatment fibrosis designation therapeutics
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
Published: 2022-09-15 (Crawled : 14:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -1.4%
H: 0.96%
C: -0.04%
therapeutics
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-09-01 (Crawled : 14:20) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 1.76%
H: 4.84%
C: 3.47%
pln-7480 fibrosis trial therapeutics review positive phase 2b
Pliant Therapeutics to Participate in BTIG Biotechnology Conference
Published: 2022-08-02 (Crawled : 14:20) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -1.15%
H: 6.87%
C: 6.01%
conference therapeutics
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
Published: 2022-07-21 (Crawled : 14:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 0.41%
H: 0.7%
C: -1.62%
pln-7480 treatment fda designation therapeutics fast track designation sclerosing cholangitis
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
Published: 2022-06-22 (Crawled : 13:20) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -1.46%
H: 9.43%
C: 5.39%
treatment preclinical therapeutics pre-clinical
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
Published: 2022-06-16 (Crawled : 13:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -4.74%
H: 3.7%
C: 2.56%
fibrosis collaboration therapeutics
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-05-03 (Crawled : 13:20) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 0.88%
H: 2.62%
C: -5.26%
pln-7480 treatment fda fibrosis designation therapeutics fast track designation
Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
Published: 2022-05-02 (Crawled : 14:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -0.85%
H: 6.37%
C: -2.75%
conference therapeutics international
CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
Published: 2022-03-17 (Crawled : 22:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -1.44%
H: 6.96%
C: 6.1%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: -0.33%
H: 5.26%
C: 4.61%
bay
Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
Published: 2022-02-28 (Crawled : 15:30) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
pln-7480 health phase 1b trial therapeutics phase 1 positive phase 2b
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
Published: 2022-01-11 (Crawled : 16:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
milestone pln-7480
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2021-11-18 (Crawled : 13:30) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 1.11%
H: 1.1%
C: -3.92%
conference therapeutics
Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 15.61%
H: 9.86%
C: -12.91%
phase 2 fibrosis positive results trial imaging phase 2b
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.